VEGFA and neoplasm: Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is clinically used with chemotherapy for patients with GBM, yet its impact on the tumor immune microenvironment remains poorly understood.